Local versus radical surgery for early rectal cancer with or without neoadjuvant or adjuvant therapy

医学 相对风险 结直肠癌 危险系数 随机对照试验 全直肠系膜切除术 荟萃分析 梅德林 新辅助治疗 临床试验 阶段(地层学) 置信区间 外科 癌症 内科学 乳腺癌 法学 古生物学 生物 政治学
作者
Mohammad Ali Kalantar Motamedi,Nicole T Mak,Carl J. Brown,Manoj Raval,Ahmer Karimuddin,Dean Giustini,P. Terry Phang
出处
期刊:The Cochrane library [Elsevier]
卷期号:2023 (6)
标识
DOI:10.1002/14651858.cd002198.pub3
摘要

Background Total mesorectal excision is the standard of care for stage I rectal cancer. Despite major advances and increasing enthusiasm for modern endoscopic local excision (LE), uncertainty remains regarding its oncologic equivalence and safety relative to radical resection (RR). Objectives To assess the oncologic, operative, and functional outcomes of modern endoscopic LE compared to RR surgery in adults with stage I rectal cancer. Search methods We searched CENTRAL, Ovid MEDLINE, Ovid Embase, Web of Science ‐ Science Citation Index Expanded (1900 to present), four trial registers (ClinicalTrials.gov, ISRCTN registry, the WHO International Clinical Trials Registry Platform, and the National Cancer Institute Clinical Trials database), two thesis and proceedings databases, and relevant scientific societies' publications in February 2022. We performed handsearching and reference checking and contacted study authors of ongoing trials to identify additional studies. Selection criteria We searched for randomized controlled trials (RCTs) in people with stage I rectal cancer comparing any modern LE techniques to any RR techniques with or without the use of neo/adjuvant chemoradiotherapy (CRT). Data collection and analysis We used standard Cochrane methodological procedures. We calculated hazard ratios (HR) and standard errors for time‐to‐event data and risk ratios for dichotomous outcomes, using generic inverse variance and random‐effects methods. We regrouped surgical complications from the included studies into major and minor according to the standard Clavien‐Dindo classification. We assessed the certainty of evidence using the GRADE framework. Main results Four RCTs were included in data synthesis with a combined total of 266 participants with stage I rectal cancer (T1‐2N0M0), if not stated otherwise. Surgery was performed in university hospital settings. The mean age of participants was above 60, and median follow‐up ranged from 17.5 months to 9.6 years. Regarding the use of co‐interventions, one study used neoadjuvant CRT in all participants (T2 cancers); one study used short‐course radiotherapy in the LE group (T1‐T2 cancers); one study used adjuvant CRT selectively in high‐risk patients undergoing RR (T1‐T2 cancers); and the fourth study did not use any CRT (T1 cancers). We assessed the overall risk of bias as high for oncologic and morbidity outcomes across studies. All studies had at least one key domain with a high risk of bias. None of the studies reported separate outcomes for T1 versus T2 or for high‐risk features. Low‐certainty evidence suggests that RR may result in an improvement in disease‐free survival compared to LE (3 trials, 212 participants; HR 1.96, 95% confidence interval (CI) 0.91 to 4.24). This would translate into a three‐year disease‐recurrence risk of 27% (95% CI 14 to 50%) versus 15% after LE and RR, respectively. Regarding sphincter function, only one study provided objective results and reported short‐term deterioration in stool frequency, flatulence, incontinence, abdominal pain, and embarrassment about bowel function in the RR group. At three years, the LE group had superiority in overall stool frequency, embarrassment about bowel function, and diarrhea. Local excision may have little to no effect on cancer‐related survival compared to RR (3 trials, 207 participants; HR 1.42, 95% CI 0.60 to 3.33; very low‐certainty evidence). We did not pool studies for local recurrence, but the included studies individually reported comparable local recurrence rates for LE and RR (low‐certainty evidence). It is unclear if the risk of major postoperative complications may be lower with LE compared with RR (risk ratio 0.53, 95% CI 0.22 to 1.28; low‐certainty evidence; corresponding to 5.8% (95% CI 2.4% to 14.1%) risk for LE versus 11% for RR). Moderate‐certainty evidence shows that the risk of minor postoperative complications is probably lower after LE (risk ratio 0.48, 95% CI 0.27 to 0.85); corresponding to an absolute risk of 14% (95% CI 8% to 26%) for LE compared to 30.1% for RR. One study reported an 11% rate of temporary stoma after LE versus 82% in the RR group. Another study reported a 46% rate of temporary or permanent stomas after RR and none after LE. The evidence is uncertain about the effect of LE compared with RR on quality of life. Only one study reported standard quality of life function, in favor of LE, with a 90% or greater probability of superiority in overall quality of life, role, social, and emotional functions, body image, and health anxiety. Other studies reported a significantly shorter postoperative period to oral intake, bowel movement, and off‐bed activities in the LE group. Authors' conclusions Based on low‐certainty evidence, LE may decrease disease‐free survival in early rectal cancer. Very low‐certainty evidence suggests that LE may have little to no effect on cancer‐related survival compared to RR for the treatment of stage I rectal cancer. Based on low‐certainty evidence, it is unclear if LE may have a lower major complication rate, but probably causes a large reduction in minor complication rate. Limited data based on one study suggest better sphincter function, quality of life, or genitourinary function after LE. Limitations exist with respect to the applicability of these findings. We identified only four eligible studies with a low number of total participants, subjecting the results to imprecision. Risk of bias had a serious impact on the quality of evidence. More RCTs are needed to answer our review question with greater certainty and to compare local and distant metastasis rates. Data on important patient outcomes such as sphincter function and quality of life are very limited. Results of currently ongoing trials will likely impact the results of this review. Future trials should accurately report and compare outcomes according to the stage and high‐risk features of rectal tumors, and evaluate quality of life, sphincter, and genitourinary outcomes. The role of neoadjuvant or adjuvant therapy as an emerging co‐intervention for improving oncologic outcomes after LE needs to be further defined.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dujinjun完成签到,获得积分10
3秒前
lysixsixsix完成签到,获得积分10
6秒前
渴望者完成签到,获得积分10
7秒前
大橙子发布了新的文献求助10
7秒前
ZQ完成签到,获得积分10
14秒前
小包子完成签到,获得积分10
15秒前
liyan完成签到 ,获得积分10
16秒前
17秒前
嗯啊完成签到,获得积分10
19秒前
酷波er应助immm采纳,获得10
20秒前
优雅含莲完成签到 ,获得积分10
20秒前
呜啦啦完成签到,获得积分10
21秒前
21秒前
lulu8809完成签到,获得积分10
24秒前
24秒前
二十五完成签到,获得积分10
25秒前
romeo完成签到,获得积分10
26秒前
kaka完成签到 ,获得积分10
26秒前
Akim应助xialuoke采纳,获得10
26秒前
昏睡的蟠桃应助guoxingliu采纳,获得200
27秒前
慕容松完成签到,获得积分10
28秒前
romeo发布了新的文献求助10
28秒前
ss_hHe完成签到,获得积分10
29秒前
29秒前
30秒前
zjcomposite完成签到,获得积分10
30秒前
nn发布了新的文献求助10
30秒前
css完成签到,获得积分10
30秒前
大橙子发布了新的文献求助10
31秒前
1111完成签到,获得积分10
31秒前
敏er好学完成签到,获得积分10
32秒前
细腻的谷秋完成签到 ,获得积分10
32秒前
独特的易形完成签到,获得积分10
33秒前
yangyangyang完成签到,获得积分0
36秒前
yirenli完成签到,获得积分10
37秒前
叶子完成签到 ,获得积分10
37秒前
angel完成签到,获得积分10
39秒前
正经大善人完成签到,获得积分10
41秒前
动听的秋白完成签到 ,获得积分10
42秒前
汉堡包应助biofresh采纳,获得30
42秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022